Principal Financial Group Inc. Has $5.37 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 89,961 shares of the specialty pharmaceutical company’s stock after buying an additional 5,829 shares during the period. Principal Financial Group Inc.’s holdings in ANI Pharmaceuticals were worth $5,367,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in shares of ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after acquiring an additional 691 shares during the last quarter. Hohimer Wealth Management LLC bought a new position in ANI Pharmaceuticals in the 3rd quarter valued at $264,000. Geode Capital Management LLC boosted its stake in ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after purchasing an additional 17,314 shares in the last quarter. Barclays PLC grew its holdings in shares of ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $405,000. 76.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,231 shares of company stock valued at $2,434,286 over the last three months. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Trading Up 2.0 %

NASDAQ ANIP opened at $55.28 on Thursday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The company has a market capitalization of $1.16 billion, a PE ratio of -100.51 and a beta of 0.73. The stock has a 50-day simple moving average of $57.09 and a 200 day simple moving average of $59.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the company posted $1.05 EPS. Research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.